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Oral PresentationsALLOGENEIC TRANSPLANTS7
FLUDARABINE, CYCLOPHOSPHAMIDE WITH OR WITHOUT LOW DOSE
TBI FOR ALTERNATIVE DONOR TRANSPLANTS IN ACQUIRED APLASTIC
ANEMIA (SAA): A REPORT FROM THE EBMT-SAA WORKING PARTY
Bacigalupo, A., Locatelli, F., Lanino, E., Marsh, J., Socie, G., Passweg, J.
Ospedale San MArtino, Genova, Italy
We have previously reported the outcome of 38 acquired SAA pa-
tients allografted from alternative donor transplants after conditioning
withfludarabine30mg/m24, cyclophosphamide300mg/m24and
rabbitATG(thymoglobulin) 3.75mg/kg 4 (BMT2005; 36:947–50):
despite anoverall survival of 73%, rejectionwashigh inpatientsover 14
years of age (32%). For this reason, in patients over the age of 14 years,
we added total body irradiation (TBI 200) to this regimen and reduced
ATG to 3.75 mg/kg  2. Pediatric patients were allowed to continue
on the non-TBI regimen. We are now reporting 70 patients, of
whom 45 were grafted with FLU-CY and 25 with FLU-CY-
TBI200.The45FLU-CYpatients, include theoriginal 38.All patients
received ATG in the conditioning. The patients were grafted between
1998 and 2007.Themedian age for the FLU-CYof age was 13 and for
the FLU-CY-TBI itwas 29 (Table) .GvHDgrade III-IVwas seen in 1
patient in each groups. Rejection was seen in 13%of the first and 12%
of the second group. Rejection was the cause of death in 3 patients in
the FLU-CY group and in 2 patients in the FLU-CY-TBI group.
The overall crude survival (80%) was excellent in both groups: the ac-
tuarial 5 year survival is 79% and 77%. The median interval from di-
agnosis to transplant was 582 days for all patients: survival was 87%
vs 65% for patients grafted before or beyond that cut off. Causes of
death were rejection (5), PTLD (2), infections (5), hemorrhage (2).
These results suggest that alternative donor transplants can be safely
performed in patients with acquired aplastic anemia, also in adults.
The persisting risk of rejection may be due to the low dose of cyclo-
phosphamide (CY) which could be significantly increased.8
FAVORABLE LEUKEMIA-FREE SURVIVAL (LFS) FOR ADULTS AND
CHILDREN UNDERGOING MYELOABLATIVE UMBILICAL CORD BLOOD
(UCB) TRANSPLANTATION WITH CYCLOPHOSPHAMIDE (CY), FLUDARA-
BINE (FLU) AND TOTAL BODY IRRADIATION (TBI): A SINGLE CENTER
ANALYSIS OF 194 PATIENTS
Brunstein, C.G., Weisdorf, D.J., DeFor, T.E., Miller, J.S.,
McGlave, P.B., Blazar, B.R., Wagner, J.E. University of Minnesota,
Minneapolis, MN
Weevaluated the outcomes in 194 consecutive patients (pts) trans-
planted with UCB after a myeloablative therapy for acute myeloid
leukemia (AML, n 5 86), acute lymphoblastic leukemia (ALL, n 5
89), chronic myeloid leukemia (CML, n 5 13), and myelodysplastic
syndrome (MDS, n 5 6) between 1995 and 2007.
Methods: Pts were assigned to 3 treatment groups: Cy 120mg/kg,
TBI 1320 cGy and equine anti-thymocyte globulin (ATG) 90mg/kg
with one UCB unit (CyTBI, 1995–2000; n5 65; median age 9 yrs, r
0.5–52); CyTBI and Flu 75mg/m2/day with one UCB unit (CY-
FluTBI-1, 2000–2007; n 5 36; median age 8yrs, r 2–44); and Cy/
Flu/TBI with twoUCB units (CyFluTBI-2, 2001–2007; n5 93; me-
dian age 25yrs, r 9–45). All received cyclosporine A (CsA) with either
short course methylprednisolone or mycophenolate mofetil. Pts
were classified as standard (acute leukemia in CR1–2 or CML in first
chronic phase, n5 138) or high risk (n5 56) for relapse.Median fol-
low-up for survivors is 2.8 years (r: 0.7–9.2). Pts received a 0–1HLA-
mismatched graft in 81% for CyFluTBI-1, 47% for CyTBI, and
36% for CyFluTBI-2 (p\.01). The total nucleated cell dose infused
in recipients of CyFluTBI-1 was 3.6 (2.1–13.9), CyTBI 3.0
(0.9–14.0), and CyFluTBI-2 3.6 (1.7–6.5)  107/kg (p 5 .01).
Results: Engraftment was not significantly different for the 3
groups (CyFluTBI-1 97% (92–100) vs. CyTBI 89% (82–96) vs.CyFluTBI-2 87% (80–94) (p 5 .06). Incidence of grades II-IV
GVHD was higher after CyFluTBI-2 (51% [40–62]) as compared
to CyFluTBI-1 (25% [11–39]) or CyTBI 37% (25–49) (p\.01) in
univariate, but not in multivariate analysis after adjusting for age
and disease risk. While treatment-related mortality (TRM) at 2 yrs
was similar in univariate analysis (CyFluTBI-1, 11% [1–21] vs.
CyFluTBI-2, 32% [22–42] vs. CyTBI 32% [22–42], p 5 .07), after
adjusting for age and disease risk TRM was higher for the CyTBI
(RR 3.5 [1.1–9.2], p 5 .03) vs. CyFluTBI-1. The relapse risk at 4
yrs for CyFluTBI-1 was 37% (19–55), CyFluTBI-2 19% (10–28),
and CyTBI 28% (18–38) (p 5 .19). The LFS at 4 yrs for Cy-
FluTBI-1 was 52% (34–70), CyFluTBI-2 49% (38–60), and CyTBI
37% (25–49) (p5 .46). Inmultivariate analysis, only high risk disease
was associated with higher relapse risk (RR 2.0; 95%CI,1.0–3.9; p5
.05) and mortality (RR 2.2;95%CI,1.4–3.4; p\.01). Notably, cell
dose and HLA match had no effect on any outcome in multivariate
analysis. In conclusion, use of two partiallyHLAmatchedUCBunits
has increased the applicability ofUCBparticularly in adult recipients.9
EVALUATION OF RABBIT ANTITHYMOCYTE GLOBULIN (RATG) DOSE-
INTENSITY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANS-
PLANTATION (ASCT) FOLLOWING REDUCED INTENSITY CONDITIONING
(RIC) WITH FLUDARABINE, BUSULFAN AND RATG (FBA)
Hamadani, M., Benson DM Jr., Jr., Porcu, P., Elder, P., Andritsos, L.,
Hofmeister, C.C., Krugh, D., Garzon, R., Lin, T., Marcucci, G.,
Blum,W., Devine, S.M. Arthur G. James Comprehensive Cancer Center,
the Ohio State University, Columbus, OH
We evaluated the effects of two doses of rATG (6.0 versus 7.5mg/
kg/total dose) in patients undergoing RIC. All patients (n5 54) were
conditioned with F (30mg/m2/day, days -7 to -3), B (0.8mg/kg/dose
IV  8 doses) and either 7.5mg/kg of rATG (7.5rA) (n 5 39) or
6.0mg/kg of rATG (6rA) (n 5 15), followed by micro-dose metho-
trexate and tacrolimus. Median age was 57 years. 76% (N 5 41)
had high-risk disease. 10 patients (18%) received mismatched allo-
grafts. 47 patients (87%) received grafts from unrelated donors. All
patients engrafted neutrophils and platelets promptly (median 15
and 17 days, respectively). One patient had secondary graft failure,
and another AML patient previously only treated with decitabine ex-
perienced secondary graft rejection. Both of these patients received
7.5rA. Compared to patients receiving 7.5rA, ones receiving 6rA
had fewer EBV (25% vs. 13%; p-value 5 0.3) CMV (61% vs.
25%; p-value5 0.05) and BK-viral (26% vs. 0%; p-value5 0.03) re-
activations and lower rates of relapse (33% vs. 6.6%; p-value5 0.04),
non-relapse mortality (28% vs. 0%; p-value 5 0.008), grade II-IV
acute GVHD (33% vs. 13%; p-value 5 0.1) and chronic GVHD
(45% vs. 13%; p-value5 0.03). None of the 6rA patients developed
PTLD. Chimerism analysis showed 100% donor CD331 chime-
rism at all time points and median donor CD31 chimerism of
94%, 97%, 99% and 100% at days 130, 160, 190 and 1180. No
difference was seen in the two rATG doses. 40 patients (74%)
were in CR after ASCT. The median follow-up of surviving patients
is 12 months (range 1–28 months). Compared to patients receiving
7.5rA, ones receiving 6rA showed trends toward improved 1-yr over-
all survival (63% vs. 100% p-value5 0.06) and progression free sur-
vival (47% vs. 91% p-value 5 0.06). Our preliminary data suggests
that 6rA promotes effective donor cell engraftment, without com-
promisingGVHDcontrol compared to 7.5rA, andmay be associated
with lower rates of infectious complications and disease relapse.
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GENOMIC INSTABILITY AFTER ALLOGENEIC HCT: FREQUENT IN ORAL
AND RARE IN NASAL MUCOSAL CELLS
Khan, F., Sy, S., Louie, P., Quinlan, D., Stewart, D., Russell, J.,
Storek, J. University of Calgary, Calgary, AB, Canada
Background: Genomic Instability (GI) is a precancerous or can-
cerous condition. Since oral carcinoma is frequent whereas nasal5
Multivariable Regression Analysis for OS and NRS† Post-
transplant variables at day 90 (±7) post-allo HCT §
OS NRS
Hospital stay (#5 vs. .5 days)* NS NS
Days of TPN (.0 vs. 0)* NS NS
PRBC transfusion (.0 vs. 0)* NS NS
Platelets transfusion (.0 vs. 0)* NS NS
Pneumonia episodes (.0 vs. 0)*,U NS p50.0008; 2.8
(1.5, 5.1)
Episodes of CMV reactivation
(.0 vs. 0)*
NS NS
Cumulative dose of steroids
(\2,650mg vs. $ 2,650mg)*
NS p50.001; 0.4
(0.2, 0.7)
Total days of steroids (\60 vs. $60)* NS NS
Dose of steroid at day 90 (67)
(\20 vs. $20mg/day)
NS NS
% weight loss (#10% vs. .10%)** NS NS
Acute GVHD (max grade) 0-I vs.
II vs. III-IV
NS NS
KPS at day 90 (67) (\80 vs. $80) p\0.0001; 4.7
(3.0, 7.4)
p\0.0001; 3.9
(2.0, 7.5)
Total bilirubin at day 90 (67)
(\1.1 vs. $1.1mg/dl)
NS NS
% Creatinine change ($30
vs.\30)*
p50.0002; 2.2
(1.5, 3.3)
NS
Albumin at day 90 (67)
\ 3.0 g/dl
vs. . 3.5 g/dl; 3.0-3.5 g/dl vs.
. 3.5 g/dl
p50.006; 2.5
(1.4, 4.5);
1.5 (0.9, 2.3)
p50.01; 3.2
(1.4, 7.1); 1.2
(0.6, 2.3)
Additional immunosuppressive
therapy (ies) (.0 vs. 0)^
NS NS
Additional anti-microbial(s)
(.0 vs. 0)^^
p50.002; 2.8
(1.5, 5.3)
NS
†Table entry: p-value (p) for the covariate effect;Hazard ratio (HR) (95%
CI).
§The effects of post-transplant variables were adjusted for baseline vari-
ables such as age, KPS and patient/donor CMV statuses in this regres-
sion, whenever appropriate/necessary. Statistical significance defined
as\0.05; NS: not significant (p$0.05). TPN: total parenteral nutrition.
*from hematopoietic engraftment until day 90 (67).
**from initiation of conditioning chemotherapy (baseline) until day 90
(67).
^additional anti-GVHD therapy(ies) apart from standard GVHD prophy-
laxis and glucocorticoids until day 90 (67).
^^additional antimicrobials apart from acyclovir, fluconazole or vorico-
nazole (whenever used for primary prohylaxis) and trimethoprin-
sulfamethoxazole (or equivalents).
Udevelopment of infiltrates requiring additional/alternative antimicro-
bials.
6 Oral Presentationscarcinoma infrequent after allo-HCT, we hypothesized that GI
could be observed in oral mucosal cells but not in nasal mucosal cells
of long-term HCT survivors.
Methods:We examined epithelial cells from buccal and nasal mu-
cosa of 71 subjects forGI at 15microsatellite loci spanning 14 human
autosomes. The study population included long-term (4–22 yrs, n5
21) and short-term (2–3 months, n 5 15) survivors of myeloablative
allo-HCT, using GVHD prophylaxis with methotrexate (day 1, 3, 6
and 11) and cyclosporine (for 3–6 months). Controls included long-
term (4–12 yrs, n5 14) and short-term (2–3months, n5 3) survivors
of myeloablative auto-HCT, 8 patients treated with intensive che-
motherapy without HCT and 5 healthy volunteers. DNA extracted
from peripheral blood leukocytes and cells of nasal and buccal mu-
cosa was PCR amplified for a panel of 15 microsatellite markers
(ABI-Identifiler). Fragment size analysis was done to identify novel
allele peaks (one that was absent in donor and recipient blood
pre-transplant but present in recipient mucosa post-transplant)
indicative of microsatellite instability (MSI).
Results:MSI was detected in 61% long-term allo-HCT survivors
in buccal mucosa, and in 5% long-term allo-HCT survivors in nasal
mucosa (p\0.001, Fisher exact test).MSI was detected in 12% short-
term allo-HCT survivors in buccal mucosa, and in 0% short-term
allo-HCT survivors in nasal mucosa (p 5 0.48). There was no asso-
ciation betweenMSI and history of clinical oral GVHD.None of the
auto-HCT survivors, patients treated with chemotherapy without
HCT or healthy volunteers showed MSI in buccal or nasal mucosal
cells. No MSI was observed in blood leukocytes of any of the above
patients or controls.
Conclusion: GI in long-term allo-HCT suvivors occurs fre-
quently in oral mucosal cells but rarely in nasal mucosal cells. As
GI was not observed in the oral mucosa of auto-HCT recipients
who received similar transplant conditioning, it cannot be due to cy-
totoxic therapy, but it should be due to a factor unique to allo-HCT,
ie, immunosuppressive drugs given forGVHDprophylaxis or graft vs
host oral mucosa reaction (even if clinically silent). The graft-vs-host
oral mucosa reaction may be more likely, as the GI was frequently
observed late posttransplant (after discontinuation of prophylactic
immunossupressive drugs) and rarely early posttransplant.
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HYPOALBUMINEMIA (\ 3.0 G/DL) AND POOR KARNOFSKY PERFOR-
MANCE (KPS\80) AT DAY 190 ARE INDEPENDENT PREDICTORS OF
WORSE NON-RELAPSE SURVIVAL (NRS) AND OVERALL SURVIVAL (OS)
IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
(ALLO-HCT) RECIPIENTS: RESULTS OF A MULTIVARIABLE ANALYSIS
Kharfan-Dabaja, M.A.1, Chavez, J.C.1, Fernandez-Vertiz, E.I.1,
Yu, D.2, Zhu, W.2, Perkins, J.1, Field, T.1, Ayala, E.1, Fernandez, H.1,
Alsina, M.1, Perez, L.1, Raychaudhuri, J.1, Ochoa-Bayona, J.L.1,
Brand, L.1, Sullivan, D.1, Anasetti, C.1 1Moffitt Cancer Center, Tampa,
FL; 2Moffitt Cancer Center, Tampa, FL
Acute GVHD (aGVHD) as a predictor of post allo-HCT survival
generally relies on criteria with significant inter-observer variability.
We study the impact of clinical, laboratory and pharmacologic pa-
rameters, during the immediate post-transplant phase [fromhemato-
logic engraftment till day 90 (67)] on NRS and OS. In this analysis,
326 consecutive pts underwent allo-HCTbetween 09/2000 until 03/
2007; 26 ptswhodiedwithin 90days from thedate of cell infusion and
3 syngeneic allo-HCTrecipientswere excluded from analysis. A total
of 297 (M/F 5 170/127) patients, median age 46 (range: 17–69) yrs
received an allo-HCT [MRD 5 154 (52%), MUD 5 109 (37%),
MMRD 5 3 (1%), MMUD 5 31 (10%)] using PBSC 5 261 (88%)
or BM 5 36 (12%) following myeloablative 5 99 (33%), RIC 5
174 (59%), orNMT5 24 (8%) for various hematologicmalignancies
stratified by CIBMTR risk [low5 87 (30%); int5 85 (29%); high5
125 (42%)]usingvariousGVHDprophylaxis regimens [MTX-based5
244 (82%); MMF-based 5 53 (18%)]. Pre-transplant variables [sig-
nificant (p\0.05) or not-significant (NS) (p$0.05) in multivariable
Cox proportional hazards regression analysis] included: age ($55
vs.\ 55 yrs) [OS: p 5 0.035, HR 5 1.6 (95% CI: 1.0–2.4); NRS:
p 5 0.03, HR 5 2.0 (95% CI: 1.1–3.6)], donor-gender [OS: NS;
NRS: NS], cell source (BM vs. PB) [OS: NS; NRS: NS], baseline
KPS (#80 vs. .80) [OS: NS; NRS: NS], CIBMTR risk (low vs.
int. vs. high) [OS: NS; NRS: NS], regimen (myeloablative vs. RIC/
NMT) [OS: NS; NRS: NS], donor/recipient matching-status
(MRD, MUD, mismatched (ref)) [OS: p 5 0.03, MRD vs. ref:HR 5 2.7 (95% CI: 1.2–6.1), MUD vs. ref: HR 5 2.7 (95% CI:
1.2- 6.1); NRS: NS], CD341 dose (\ 3  106/kg, 3–7.9  106/kg,
$8 106/kg) [OS:NS;NRS:NS],GVHDprophylaxis (MTX-based
vs. MMF-based) [OS: NS; NRS: NS], recipient/donor CMV status
[OS: NS; NRS: NS]. Multivariable regression analysis of post-trans-
plant variables at day 90 show that a KPS\80 and hypoalbuminemia
\3.0 g/dl are independent predictors of worseNRS andOS. A wors-
ening serum creatinine ($30%) and additional antimicrobials apart
from standard prophylaxis are independent predictors of worse OS;
whereas pneumonia (.0 episode by day 90) and cumulative dose of
prednisone exceeding 2,650 mg are independent predictors of worse
NRS. A KPS \80 and hypoalbuminemia (\3.0 g/dl), at day 90,
important predictors of survival that should be considered when
prognosticating outcome after allo-HCT.12
RAPID IMMUNOSUPPRESSION TAPER FOLLOWING REDUCED INTENSITY
HCT FROM RELATED DONOR IS TOLERABLE BUT DOES NOT IMPROVE
OUTCOMES OF ADVANCED HEMATOLOGIC MALIGNANCIES
Krijanovski, O.1, Krijanovski, Y.2, Khaled, Y.1, Cummings, T.1,
Braun, T.1, Reddy, P.1, Peres, E.1, Mineishi, S.1, Kitko, C.1, Choi, S.1,
